GALENA BIOPHARMA INC COM
RXII
RXII was delisted on the 25th of October, 2011.
0 hedge funds and large institutions have $0 invested in GALENA BIOPHARMA INC COM in 2016 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 91 closing their positions.
100% less funds holding
Funds holding: 92 → 0 (-92)
100% less capital invested
Capital invested by funds: $11.8M → $0 (-$11.8M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 91
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.93M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$2.11M |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$1.54M |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.01M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$715K |
RXII Hedge Fund Activity: Q4 2016 in Review
0 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in GALENA BIOPHARMA INC COM (RXII) for Q4 2016, worth a combined $0 — down 100% from $11.8M a quarter earlier.
Sellers outnumbered buyers: 91 funds closed out of RXII and 0 opened new positions — a net loss of 91 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Vanguard Group, exiting entirely with an estimated $2.93M sold.
- 0 institutional investors held GALENA BIOPHARMA INC COM (RXII) as of Q4 2016, down from 92 in Q3 2016.
- Funds reported $0 of GALENA BIOPHARMA INC COM stock for Q4 2016, down 100% quarter-over-quarter.
- 0 funds opened new GALENA BIOPHARMA INC COM positions in Q4 2016 and 91 closed out, a net change of -91 holders.
- The largest GALENA BIOPHARMA INC COM seller in Q4 2016 was Vanguard Group, an estimated $2.93M sold.
Based on aggregated 13F filings for Q4 2016.